Learn how dynamic, preventive plan strategies can bring improved life experience and savings to employers and employees alike!

At this event we will explore:

Importance of clear and objective financial information on the progression of chronic conditions
How early detection can coordinate with wellness and care management programs for improved outcomes
How genetic testing is impacting the practice of medicine and improving health and well-being

Click here to register.

Self-Funding 101

This session is dedicated to helping employers who are currently choosing to fully insure their medical plan to learn about the components of self-funding, why employers are considering this funding option and how it can impact their bottom line. This is a basic introduction to self-funding that will be followed by advanced concepts in self-funding session in February. We have a special guest at this session, Matt Fish, President of Vital Plastics, to share how he manages the financial aspect of running the plan.

How preventive eye exams can predict future health care needs

• Conditions that can be predicted through routine eye exams,
• How early detection can coordinate with wellness and care management programs for improved outcomes,
• Latest concerns in eye health, and
• How technology advances may change the way in which we uncover overall health issues.

Derailing the trend for poor health and rising healthcare expenses

• Understand the root cause of less health and the pillars to improve health,
• Importance of clear and objective financial information on the progression of chronic conditions,
• Information on why late diagnosis impacts disease burden and cost of care, and
• Strategies to improve health outcomes.

How Genetic Testing Improves Prevention, Diagnosis and Treatment of Disease

• Understand DNA and its importance in new medical advancements,
• How we can prevent disease before it happens,
• How genetic testing is impacting the practice of medicine and improving health and well-being, and
• Learn about proactive testing for inherited disease risk, pharmacogenomics for drug response, and
  biomarker profiling for targeted treatments in cancer.